Home > Newsletters > FDAnews Drug Daily Bulletin > EU to Wait for More Experience Before Issuing Companion Dx Guidance
FDAnews Drug Daily Bulletin
Sept. 4, 2012 | Vol. 9 No. 173
EU to Wait for More Experience Before Issuing Companion Dx Guidance
Known for its relatively relaxed regulations on companion diagnostics (CDx), the European Medicines Agency (EMA) is not expected to provide guidance on the products until it has more experience in this area, an expert says. Once it does, the regulation of CDx in Europe is likely to change under an upcoming revision of the European Commission’s in vitro diagnostic (IVD) directive. The revision would make CDx Class C devices and require notified body involvement for review of technical documentation, Bruno Flamion, former chair of the EMA’s Scientific Advice Working Party, said at the Next Generation Summit in Washington, D.C., Aug. 22.
Clinical Trials Advisor
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.